NOVARTIS' Jakavi (ruxolitinib), a JAK1/2 inhibitor, is now listed on the PBS for patients aged 12 years and older with acute or chronic graft-versus-host disease (GvHD), who have inadequate response to corticosteroids or other systemic treatments.
Jakavi is a first-in-class treatment option for patients living with acute or chronic GvHD, offering an alternative to the standard approach of using high dose steroids, which can have serious side effects, especially when used long term.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Apr 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Apr 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
